In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines

Saverio Savini, Wainer Zoli, Oriana Nanni, Annalisa Volpi, G. Luca Frassineti, Enrico Magni, Alberto Flamigni, Andrea Amadori, Dino Amadori

Research output: Contribution to journalArticle

Abstract

Lonidamine is a new potential chemotherapeutic agent, relatively non-toxic, that can positively modulate the efficacy of several antineoplastic drugs. We evaluated the response of two established human breast cancer cell lines (MCF-7 and BRC-230) and of 20 primary breast cancer cell lines to lonidamine, either alone or in combination with adriamycin, the drug most widely used in the management of breast cancer. Different schedules were tested by varying either concentration of the drugs (LND: 10-150μg/ml; ADM: 0.10-0.15μg/ml), or time of exposure (1-96 hours), or sequence of administration (ADM → LND; LND → ADM; ADM + LND). Our results indicate slight sensitivity of the cell lines to lonidamine when used alone, whereas an increase of efficacy was noted when lonidamine was added for at least 24 hours after a 4 hour exposure to adriamycin. Such efficacy was significantly greater than that expected from an additive effect between the two drugs. We conclude that lonidamine, when given according to an appropriate schedule, enhances, in vitro, the efficacy of adriamycin. A correct employment of lonidamine in the management of breast cancer might therefore potentiate the therapeutic effect of adriamycin.

Original languageEnglish
Pages (from-to)27-34
Number of pages8
JournalBreast Cancer Research and Treatment
Volume24
Issue number1
DOIs
Publication statusPublished - Feb 1992

Fingerprint

Doxorubicin
Breast Neoplasms
Cell Line
Appointments and Schedules
Pharmaceutical Preparations
Therapeutic Uses
Antineoplastic Agents
lonidamine
In Vitro Techniques

Keywords

  • adriamycin
  • breast cancer
  • chemosensitivity assay
  • lonidamine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines. / Savini, Saverio; Zoli, Wainer; Nanni, Oriana; Volpi, Annalisa; Frassineti, G. Luca; Magni, Enrico; Flamigni, Alberto; Amadori, Andrea; Amadori, Dino.

In: Breast Cancer Research and Treatment, Vol. 24, No. 1, 02.1992, p. 27-34.

Research output: Contribution to journalArticle

Savini, Saverio ; Zoli, Wainer ; Nanni, Oriana ; Volpi, Annalisa ; Frassineti, G. Luca ; Magni, Enrico ; Flamigni, Alberto ; Amadori, Andrea ; Amadori, Dino. / In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines. In: Breast Cancer Research and Treatment. 1992 ; Vol. 24, No. 1. pp. 27-34.
@article{13147f5b39c0482d980ffe77feaefcf6,
title = "In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines",
abstract = "Lonidamine is a new potential chemotherapeutic agent, relatively non-toxic, that can positively modulate the efficacy of several antineoplastic drugs. We evaluated the response of two established human breast cancer cell lines (MCF-7 and BRC-230) and of 20 primary breast cancer cell lines to lonidamine, either alone or in combination with adriamycin, the drug most widely used in the management of breast cancer. Different schedules were tested by varying either concentration of the drugs (LND: 10-150μg/ml; ADM: 0.10-0.15μg/ml), or time of exposure (1-96 hours), or sequence of administration (ADM → LND; LND → ADM; ADM + LND). Our results indicate slight sensitivity of the cell lines to lonidamine when used alone, whereas an increase of efficacy was noted when lonidamine was added for at least 24 hours after a 4 hour exposure to adriamycin. Such efficacy was significantly greater than that expected from an additive effect between the two drugs. We conclude that lonidamine, when given according to an appropriate schedule, enhances, in vitro, the efficacy of adriamycin. A correct employment of lonidamine in the management of breast cancer might therefore potentiate the therapeutic effect of adriamycin.",
keywords = "adriamycin, breast cancer, chemosensitivity assay, lonidamine",
author = "Saverio Savini and Wainer Zoli and Oriana Nanni and Annalisa Volpi and Frassineti, {G. Luca} and Enrico Magni and Alberto Flamigni and Andrea Amadori and Dino Amadori",
year = "1992",
month = "2",
doi = "10.1007/BF01832355",
language = "English",
volume = "24",
pages = "27--34",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines

AU - Savini, Saverio

AU - Zoli, Wainer

AU - Nanni, Oriana

AU - Volpi, Annalisa

AU - Frassineti, G. Luca

AU - Magni, Enrico

AU - Flamigni, Alberto

AU - Amadori, Andrea

AU - Amadori, Dino

PY - 1992/2

Y1 - 1992/2

N2 - Lonidamine is a new potential chemotherapeutic agent, relatively non-toxic, that can positively modulate the efficacy of several antineoplastic drugs. We evaluated the response of two established human breast cancer cell lines (MCF-7 and BRC-230) and of 20 primary breast cancer cell lines to lonidamine, either alone or in combination with adriamycin, the drug most widely used in the management of breast cancer. Different schedules were tested by varying either concentration of the drugs (LND: 10-150μg/ml; ADM: 0.10-0.15μg/ml), or time of exposure (1-96 hours), or sequence of administration (ADM → LND; LND → ADM; ADM + LND). Our results indicate slight sensitivity of the cell lines to lonidamine when used alone, whereas an increase of efficacy was noted when lonidamine was added for at least 24 hours after a 4 hour exposure to adriamycin. Such efficacy was significantly greater than that expected from an additive effect between the two drugs. We conclude that lonidamine, when given according to an appropriate schedule, enhances, in vitro, the efficacy of adriamycin. A correct employment of lonidamine in the management of breast cancer might therefore potentiate the therapeutic effect of adriamycin.

AB - Lonidamine is a new potential chemotherapeutic agent, relatively non-toxic, that can positively modulate the efficacy of several antineoplastic drugs. We evaluated the response of two established human breast cancer cell lines (MCF-7 and BRC-230) and of 20 primary breast cancer cell lines to lonidamine, either alone or in combination with adriamycin, the drug most widely used in the management of breast cancer. Different schedules were tested by varying either concentration of the drugs (LND: 10-150μg/ml; ADM: 0.10-0.15μg/ml), or time of exposure (1-96 hours), or sequence of administration (ADM → LND; LND → ADM; ADM + LND). Our results indicate slight sensitivity of the cell lines to lonidamine when used alone, whereas an increase of efficacy was noted when lonidamine was added for at least 24 hours after a 4 hour exposure to adriamycin. Such efficacy was significantly greater than that expected from an additive effect between the two drugs. We conclude that lonidamine, when given according to an appropriate schedule, enhances, in vitro, the efficacy of adriamycin. A correct employment of lonidamine in the management of breast cancer might therefore potentiate the therapeutic effect of adriamycin.

KW - adriamycin

KW - breast cancer

KW - chemosensitivity assay

KW - lonidamine

UR - http://www.scopus.com/inward/record.url?scp=0027099855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027099855&partnerID=8YFLogxK

U2 - 10.1007/BF01832355

DO - 10.1007/BF01832355

M3 - Article

C2 - 1463869

AN - SCOPUS:0027099855

VL - 24

SP - 27

EP - 34

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -